Economic evaluation of vaccines: Specificities and future challenges illustrated by recent European examples

Expert Review of Vaccines

Volumn 12, Issue 5, 2013, Pages 555-565

  Postma, Maarten J ^a   Westra, Tjalke A ^a   Quilici, Sibilia ^b   Largeron, Nathalie ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SANOFI PASTEUR   (France)

Author keywords

cost effectiveness; health economics; prevention; vaccines

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW;

COSTS AND COST ANALYSIS; EUROPE; HUMANS; MODELS, STATISTICAL; VACCINATION; VACCINES;

EID: 84877609276     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.36     Document Type: Review

References (78)

1. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect. Dis. 8(11), 727-733 (2008).
2. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 28(11), 2356-2359 (2010).
3. Szucs TD. Health economic research on vaccinations and immunisation practices-an introductory primer. Vaccine 23(17-18), 2095-2103 (2005).
4. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 25(32), 5945-5957 (2007).
5. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and 'no medical care' disease impact in Belgium. Med. Decis. Making 29(1), 33-50 (2009).
6. Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 27(44), 6121-6128 (2009).
7. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337, a769 (2008).
8. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in The Netherlands; the results of a consensus model. BMC Public Health 11, 462 (2011).
9. Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 340, c2509 (2010).
10. Postma MJ. Public health economics of vaccines in The Netherlands: methodological issues and applications. Public Health 16(4), 267-273 (2008).
11. Coupé VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int. J. Cancer 124(4), 970-978 (2009).
12. de Kok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in The Netherlands. J. Natl Cancer Inst. 101(15), 1083-1092 (2009).
13. Postma MJ. Cost-effectiveness analysis of human papillomavirus (HPV) vaccination in The Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion. Vaccine 28(4), 873-874 (2010).
14. Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in The Netherlands. Vaccine 27(35), 4776-4783 (2009).
15. Rozenbaum MH, Boersma C. Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in The Netherlands. J. Natl Cancer Inst. 102(5), 358-359; author reply 359 (2010).
16. Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (Prevenar 13®). Drugs 70(15), 1973-1986 (2010).
17. Klok R, Strutton DR, Postma MJ. Public health and economic impact of 13-valent pneumococcal conjugate vaccination in The Netherlands. Presented at: 27th Annual Meeting of the European Society of Paediatric Infectious Diseases. Brussels, Belgium, 9-13 June 2009.
18. Einstein MH, Baron M, Levin MJ, et al.; HPV-010 Study Group. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5(10), 705-719 (2009).
19. Vessey SJ, Chan CY, Kuter BJ, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J. Pediatr. 139(2), 297-304 (2001).
20. Roteli-Martins CM, Naud P, De Borba P et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 8(3), 390-397 (2012).
21. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J. Epidemiol. Community Health 55(2), 123-125 (2001).
22. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
23. Klok RM, Brouwer WB, Annemans L, Bos JM, Postma MJ. Towards a healthier discount procedure. Expert Rev. Pharmacoecon. Outcomes Res. 5(1), 59-63 (2005).
24. Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Manag. Sci. 29, 300-306 (1983).
25. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ. 10(7), 587-599 (2001).
26. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 331(7514), 446-448 (2005).
27. Claxton K, Sculpher M, Culyer A, et al. Discounting and cost-effectiveness in NICE-stepping back to sort out a confusion. Health Econ. 15(1), 1-4 (2006).
28. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on dutch drug expenditures using retrospective analysis. Value Health 13(6), 853-856 (2010).
29. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25(29), 5399-5408 (2007).
30. Westra TA, Rozenbaum MH, Rogoza RM et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J. Infect. Dis. 204(3), 377-384 (2011).
31. Westra TA, Stirbu I, Dorsman S, et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papilloma virus vaccination in The Netherlands. Vaccine 13, 75 (2013).
32. de Vries R, Kretzschmar M, Schellekens JF et al. Cost-effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010).
33. Rozenbaum MH, De Cao E, Postma MJ. Cost-effectiveness of pertussis booster vaccination in The Netherlands. Vaccine 30(50), 7327-7331 (2012).
34. O'Mahony JF. Re: Cost-effectiveness of pertussis booster vaccination in The Netherlands. Vaccine 30(50), 7141 (2012).
35. Rozenbaum MH, Postma MJ. Response on 'Re: cost-effectiveness of pertussis booster vaccination in The Netherlands'. Vaccine 31(16), 2024 (2012).
36. Postma MJ, Parouty M, Westra TA. Accumulating evidence for the case of differential discounting. Expert Rev. Clin. Pharmacol. 6(1), 1-3 (2013).
37. Loewenstein GF, Prelec D. Anomalies in intertemporal choice: evidence and an interpretation. Quart. J. Econ. 107, 573-597 (1992).
38. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med. Care 27(Suppl. 3), S233-S253 (1989).
39. Bos JM, Beutels P, Annemans L, Postma MJ. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 22(18), 1171-1179 (2004).
40. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press, NY, USA, 176-209 (1996).
41. Bazelon B, Smetters K. Discounting in the long term. Loyala Los Angeles Law Rev. 35(1), 277 (2002).
42. O'Mahony JF, de Kok IM, van Rosmalen J, Habbema JD, Brouwer W, van Ballegooijen M. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health 14(4), 438-442 (2011).
43. Westra TA, Parouty MB, Wilschut JC, Boersma C, Postma MJ. Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health 14, 1173-1174 (2011).
44. Bos JM, Alphen Lv, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev. Pharmacoecon. Outcomes Res. 2(5), 443-455 (2002).
45. Pitman R, Fisman D, Zaric GS, et al.; ISPOR-SMDM Modeling Good Research Practices Task Force. Dynamic transmission modeling: a report of the ISPORSMDM Modeling Good Research Practices Task Force-5. Value Health 15(6), 828-834 (2012).
46. Anonychuk A, Krahn M. Health economic and infectious disease modelling: a guide to merging streams. Pharmacoeconomics 29(5), 367-369 (2011).
47. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 29(5), 371-386 (2011).
48. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modeling approaches. Pharmacoeconomics 26(3), 191-215 (2008).
49. Ethgen O, Standaert B. Population-versus cohort-based modelling approaches. Pharmacoeconomics 30(3), 171-181 (2012).
50. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect. Dis. 10, 90 (2010).
51. Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health 14(8), 1028-1038 (2011).
52. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 28(33), 5473-5484.
53. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12(2), 226-233 (2009).
54. de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ; PILOT-CT Study Group. Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. Value Health 9(1), 1-11 (2006).
55. Welte R, Kretzschmar M, van den Hoek JA, Postma MJ. A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis. Sex. Transm. Infect. 79(5), 426 (2003).
56. Lugnér AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ. 19(5), 518-531 (2010).
57. Postma MJ, Bos JM, Beutels P, Schilthuis H, van den Hoek JA. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 22(15-16), 1862-1867 (2004).
58. De Vries R. Health-Economics of Interventions Aimed at Infectious Diseases: Dynamic Modeling Inevitable for Reliable Medical Decision Making. University of Groningen, Groningen, The Netherlands (2010).
59. Postma MJ, Baltussen RP, Palache AM, Wilschut JC. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev. Pharmacoecon. Outcomes Res. 6(2), 215-227 (2006).
60. Brisson M, Van de Velde N, Boily MC. Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex. Transm. Infect. 87(1), 41-43 (2011).
61. Bogaards JA, Coupé VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Longterm impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 22(4), 505-515 (2011).
62. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 28(24), 4091-4102 (2010).
63. Bonanni P, Breuer J, Gershon A, et al. Varicella vaccination in Europe-taking the practical approach. BMC Med. 7, 26 (2009).
64. Westra TA, Parouty M, Brouwer WB, et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 15(3), 562-567 (2012).
65. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 20(1), 2-15 (2011).
66. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5(3), e74 (2008).
67. Marsh K, Phillips CJ, Fordham R, Bertranou E, Hale J. Estimating cost-effectiveness in public health: a summary of modeling and valuation methods. Health Econ. Rev. 2(1), 17 (2012).
68. Connolly MP, Topachevskyi O, Standaert B, Ortega O, Postma M. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics 30(8), 681-695 (2012).
69. Bärnighausen T, Bloom DE, Canning D et al. Rethinking the benefits and costs of childhood vaccination: the example of the haemophilus influenzae type b vaccine. Vaccine 29(13), 2371-2380 (2011).
70. Smith RD, Keogh-Brown MR, Barnett T, Tait J. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. BMJ 339, b4571 (2009).
71. Postma MJ, Standaert BA. Economics of vaccines revisited. Hum. Vaccin. Immunother. 9(5), (2013).
72. European Medicines Agency. www.ema.europa.eu (Accessed April 2012)
73. Dutch Health Council. www.gr.nl (Accessed April 2012)
74. National Institute of Clinical Excellence. www.nice.org.uk (Accessed April 2012)
75. Health Council Belgium. www.kce.fgov.be (Accessed April 2012)
76. Pharmacoeconomic Guidelines Around The World. www.ispor.org/PEguidelines/ index.asp (Accessed April 2012)
77. UK Treasury. www.hm-treasury.gov.uk/green-book- guidance-discounting.htm (Accessed April 2012)
78. Dutch Health Care Insurance Board. www.cvz.nl (Accessed April 2012)